167 related articles for article (PubMed ID: 38601689)
1. Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination.
Montmaneix-Engels F; Dimeglio C; Staes L; Da Silva I; Porcheron M; Jougla I; Hérin F; Izopet J
Heliyon; 2024 Apr; 10(7):e29116. PubMed ID: 38601689
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: An observational study.
Stambouli N; Bahrini K; Romdhani C; Rebai A; Boughariou S; Zakraoui M; Arfaoui B; Seyli S; Boukhalfa Y; Battikh R; Moussa MB; Labbene I; Ferjani M; Gharssallah H
J Immunol Methods; 2024 May; 528():113665. PubMed ID: 38490578
[TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma release assays outcomes in healthy subjects following BNT162b2 mRNA COVID-19 vaccination.
Kurteva E; Vasilev G; Tumangelova-Yuzeir K; Ivanova I; Ivanova-Todorova E; Velikova T; Kyurkchiev D
Rheumatol Int; 2022 Mar; 42(3):449-456. PubMed ID: 35059799
[TBL] [Abstract][Full Text] [Related]
6. Cell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens.
Culebras E; Martínez M; Novella C; León JM; Marcos E; Delgado-Iribarren A; Ríos E
Front Cell Infect Microbiol; 2024; 14():1370859. PubMed ID: 38572317
[TBL] [Abstract][Full Text] [Related]
7. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
Salvagno GL; Pighi L; Henry BM; Valentini M; Tonin B; Bragantini D; Gianfilippi G; De Nitto S; Plebani M; Lippi G
Clin Chem Lab Med; 2023 Jun; 61(7):1343-1348. PubMed ID: 36722026
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants.
Vogrig M; Berger AE; Bourlet T; Waeckel L; Haccourt A; Chanavat A; Hupin D; Roche F; Botelho-Nevers E; Pozzetto B; Paul S
J Clin Immunol; 2023 Jan; 43(1):31-45. PubMed ID: 36006568
[TBL] [Abstract][Full Text] [Related]
9. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
[TBL] [Abstract][Full Text] [Related]
11. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
13. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
14. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
15. Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France.
Graça D; Brglez V; Allouche J; Zorzi K; Fernandez C; Teisseyre M; Cremoni M; Benzaken S; Pradier C; Seitz-Polski B
J Clin Immunol; 2023 Nov; 43(8):1724-1739. PubMed ID: 37606852
[TBL] [Abstract][Full Text] [Related]
16. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
Front Immunol; 2022; 13():907615. PubMed ID: 35812459
[TBL] [Abstract][Full Text] [Related]
17. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
18. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
19. Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
Cerna K; Duricova D; Hindos M; Hindos Hrebackova J; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kastylova K; Teplan V; Lukas M
J Crohns Colitis; 2022 Sep; 16(9):1347-1353. PubMed ID: 35358307
[TBL] [Abstract][Full Text] [Related]
20. Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study.
Sim W; Kang H; Jung J; Lee J; Ko GY; Park HS; Choi J; Park K; Oh EJ
Front Immunol; 2023; 14():1120556. PubMed ID: 36936965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
